Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Claims cover method of treating a viral infection with a lectin-binding carbohydrate
BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
Related news for (BIXT)
- Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
- Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission
- Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
- Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens